ScripThis year’s American Society of Hematology (ASH) meeting delivered positive Phase II results for a new daily oral therapy and promising interim Phase I/II data for a one-time base editing treatment fo
Pink SheetLess than a year ago, Pfizer Inc. was securing reimbursement in the UK for its sickle cell disease (SCD) drug, Oxbryta (voxelitor), while hematologists were debating how the increasing number of opt
ScripLess than a year ago, Pfizer Inc. was securing reimbursement in the UK for its sickle cell disease (SCD) drug, Oxbryta (voxelitor), while hematologists were debating how the increasing number of opt
ScripScrip regularly covers business development and deal-making in the biopharmaceutical industry. Deal Watch is supported by deal intelligence from Biomedtracker. Emmaus, Kainos Tie Up To Develop IRAK4